Drugs & Aging

, Volume 22, Issue 10, pp 823–844 | Cite as

Aetiology and Management of Male Erectile Dysfunction and Female Sexual Dysfunction in Patients with Cardiovascular Disease

  • Stephen L. Archer
  • Ferrante S. Gragasin
  • Linda Webster
  • Derek Bochinski
  • Evangelos D. Michelakis
Therapy In Practice

Abstract

The historical basis for understanding erectile function as a neurovascular phenomenon and the advance from fanciful to effective treatment of erectile dysfunction (ED) are reviewed, with emphasis on patients with cardiovascular disease (CVD). ED occurs in 60% of CVD patients by 40 years of age. Male ED and female sexual dysfunction (FSD) diminish quality of life and often warn of occult CVD. ED is often unrecognised but is readily diagnosed during a 5-minute interview using a truncated International Index of Erectile Function questionnaire. Erection of the penis and clitoral engorgement result from local, arousal-induced release of neuronal and endothelial-derived nitric oxide (NO). Arterial vasodilatation and relaxation of cavernosal smooth muscle cells cause arterial blood to flood trabecular spaces, compressing venous drainage, resulting in tumescence. Cyclic guanosine monophosphate (cGMP)-induced activation of protein kinase G mediates the effects of NO by enhancing calcium sequestration and activating large-conductance, calcium-sensitive K+ channels. Future treatment strategies will likely enhance these pathways. Phosphodiesterase-5 inhibitors (sildenafil, tadalafil and vardenafil) increase cGMP levels in erectile tissue. These agents are effective in 80% of CVD patients with ED and can be used safely, even in the presence of stable coronary disease or congestive heart failure, provided nitrates are avoided and patients do not have hypotension, severe aortic stenosis or evocable myocardial ischaemia. Second-line therapies (vacuum constrictor device and transurethral or intracavernosal prostaglandin E1) can also be used in CVD patients. Treatment of FSD and its relationship to CVD are less well established, but similarities to ED exist. ED can be prevented by reduction of CVD risk factors, exercise, weight loss and abstinence from smoking.

Notes

Acknowledgements

Drs Michelakis and Archer are supported by the Canada Foundation for Innovation, the Alberta Heart and Stroke Foundation, the Canadian Institutes for Health Research (CIHR), and ABACUS (the Alberta Cardiovascular and Stroke Research Centre). Dr Archer is a Canada Research Chair in Oxygen Sensing and Translational Cardiovascular Research and is supported by NIH-RO1-HL071115. Dr Michelakis is a Canada Research Chair in Pulmonary Hypertension and a Scholar of the Alberta Heritage Foundation for Medical Research (AHFMR).

The authors have no conflicts of interest that are directly relevant to the content of this review.

References

  1. 1.
    NIH Consensus Conference. NIH consensus development panel on impotence. JAMA 1993; 270: 83–90CrossRefGoogle Scholar
  2. 2.
    Johannes CB, Araujo AB, Feldman HA, et al. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts male aging study. J Urol 2000; 163: 460–3PubMedCrossRefGoogle Scholar
  3. 3.
    Tardif GS. Sexual activity after a myocardial infarction. Arch Phys Med Rehabil 1989; 70: 763–6PubMedGoogle Scholar
  4. 4.
    DeBusk RF. Evaluating the cardiovascular tolerance for sex. Am J Cardiol 2000; 86: 51F–6FPubMedCrossRefGoogle Scholar
  5. 5.
    DeBusk R, Drory Y, Goldstein I, et al. Management of sexual dysfunction in patients with cardiovascular disease: recommendations of the Princeton Consensus Panel. Am J Cardiol 2000; 86: 62F–8FPubMedCrossRefGoogle Scholar
  6. 6.
    Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54–61PubMedGoogle Scholar
  7. 7.
    Nemec ED, Mansfield L, Kennedy JW. Heart rate and blood pressure responses during sexual activity in normal males. Am Heart J 1976; 92: 274–7PubMedCrossRefGoogle Scholar
  8. 8.
    Pashkow FJ, Dafoe WA, editors. Cardiac rehabilitation: a cardiologist’s guide. Baltimore (MD): Williams and Wilkins, 1993Google Scholar
  9. 9.
    Conti CR, Pepine CJ, Sweeney M. Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease. Am J Cardiol 1999; 83: 29C–34CPubMedCrossRefGoogle Scholar
  10. 10.
    Rosen RC, Cappelleri JC, Smith MD, et al. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 1999; 11: 319–26PubMedCrossRefGoogle Scholar
  11. 11.
    Kloner RA, Mullin SH, Shook T, et al. Erectile dysfunction in the cardiac patient: how common and should we treat? J Urol 2003; 170: S46–50PubMedCrossRefGoogle Scholar
  12. 12.
    Ignarro LJ, Bush PA, Buga GM, et al. Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscle. Biochem Biophys Res Commun 1990; 170: 843–50PubMedCrossRefGoogle Scholar
  13. 13.
    Gragasin FS, Michelakis ED, Hogan A, et al. The neurovascular mechanism of clitoral erection: nitric oxide and cGMP-stimulated activation of BKCa channels. FASEB J 2004; 18: 1382–91PubMedCrossRefGoogle Scholar
  14. 14.
    Rajfer J, Aronson WJ, Bush PA, et al. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med 1992; 326: 90–4PubMedCrossRefGoogle Scholar
  15. 15.
    Cellek S, Moncada S. Nitrergic neurotransmission mediates the non-adrenergic non-cholinergic responses in the clitoral corpus cavernosum of the rabbit. Br J Pharmacol 1998; 125: 1627–9PubMedCrossRefGoogle Scholar
  16. 16.
    Dunsmuir W. History of erectile dysfunction. In: Carson CC, Kirby RS, editors. Textbook of erectile dysfunction. Oxford: ISIS Medical Media, 1999: 3–13Google Scholar
  17. 17.
    van Driel MF, van de Wiel HB, Mensink HJ. Some mythologic, religious, and cultural aspects of impotence before the present modern era. Int J Impot Res 1994; 6: 163–9PubMedGoogle Scholar
  18. 18.
    de Graaf R. Tractatus de virorum organis. In Opera Omnia. Ex Officina Hackiana 1667: 1–53Google Scholar
  19. 19.
    Eckhard C. Untersuchungen uber die erection des penis beim hunde. Beitr Anat Physiol 1863; 3: 123–50Google Scholar
  20. 20.
    Voronoff S. Rejuvenation by grafting. In: Allen G, editor. London: Allen and Unwin, 1925: 1–67Google Scholar
  21. 21.
    Lespinasse V. Impotency: its treatment by transplantation of the testicle. Surg Clin Chicago 1918; 2: 281–8Google Scholar
  22. 22.
    Lowenstein J. History and literature of mechanotherapy. The treatment of impotence: with special reference to mechanotherapy. London: Hamish Hamilton, 1947: 13–21Google Scholar
  23. 23.
    Thorek M. Steinach’s vasoligation experiments and so called rejuvenation: the human testis. Philadelphia (PA): Lippincott, 1942: 285–97Google Scholar
  24. 24.
    Hammond T. The function of the testis after puberty. Br J Urol 1924; 6: 128–41CrossRefGoogle Scholar
  25. 25.
    Virag R. Intracavernous injection of papaverine for erectile failure [letter]. Lancet 1982; II: 938CrossRefGoogle Scholar
  26. 26.
    Brindley GS. Cavernosal alpha-blockade: a new technique for investigating and treating erectile impotence. Br J Psychiatry 1983; 143: 332–7PubMedCrossRefGoogle Scholar
  27. 27.
    Campbell SF. Science, art and drug discovery: a personal perspective. Clin Sci (Lond) 2000; 99: 255–60CrossRefGoogle Scholar
  28. 28.
    Carson III CC. Sildenafil: a 4-year update in the treatment of 20 million erectile dysfunction patients. Curr Urol Rep 2003; 4: 488–96PubMedCrossRefGoogle Scholar
  29. 29.
    Archer S, Huang J, Hampl V, et al. Nitric oxide and cGMP cause vasorelaxation by activation of a charybdotoxin-sensitive K channel by cGMP-dependent protein kinase. Proc Natl Acad Sci U S A 1994; 91: 7583–7PubMedCrossRefGoogle Scholar
  30. 30.
    Robertson BE, Schubert R, Hescheler J, et al. cGMP-dependent protein kinase activates Ca-activated K channels in cerebral artery smooth muscle cells. Am J Physiol 1993; 265: C299–303PubMedGoogle Scholar
  31. 31.
    Twort CH, van Breemen C. Cyclic guanosine monophosphate-enhanced sequestration of Ca2+ by sarcoplasmic reticulum in vascular smooth muscle. Circ Res 1988; 62: 961–4PubMedCrossRefGoogle Scholar
  32. 32.
    Xiong Z, Sperelakis N. Regulation of L-type calcium channels of vascular smooth muscle cells. J Mol Cell Cardiol 1995; 27: 75–91PubMedCrossRefGoogle Scholar
  33. 33.
    Bonnevier J, Fassler R, Somlyo AP, et al. Modulation of Ca2+ sensitivity by cyclic nucleotides in smooth muscle from protein kinase G-deficient mice. J Biol Chem 2004; 279: 5146–51PubMedCrossRefGoogle Scholar
  34. 34.
    Christ G, Rehman J, Day N, et al. Intracorporal injection of hSlo cDNA in rats produces physiologically relevant alterations in penile function. Am J Physiol 1998; 275: H600–8PubMedGoogle Scholar
  35. 35.
    Archer SL. Potassium channels and erectile dysfunction. Vascul Pharmacol 2002; 38: 61–71PubMedCrossRefGoogle Scholar
  36. 36.
    Araujo AB, Durante R, Feldman HA, et al. The relationship between depressive symptoms and male erectile dysfunction: cross-sectional results from the Massachusetts Male Aging Study. Psychosom Med 1998; 60: 458–65PubMedGoogle Scholar
  37. 37.
    Goldstein I. The mutually reinforcing triad of depressive symptoms, cardiovascular disease, and erectile dysfunction. Am J Cardiol 2000; 86(2A): 41F–5FPubMedCrossRefGoogle Scholar
  38. 38.
    Langtry HD, Markham A. Sildenafil: a review of its use in erectile dysfunction. Drugs 1999; 57: 967–89PubMedCrossRefGoogle Scholar
  39. 39.
    Mertens C, Merckx L, Derluyn M, et al. Iatrogenic femoral arteriovenous fistula as a cause of erectile dysfunction. Eur Urol 1994; 26: 340–1PubMedGoogle Scholar
  40. 40.
    Jaarsma T, Dracup K, Walden J, et al. Sexual function in patients with advanced heart failure. Heart Lung 1996; 25: 262–70PubMedCrossRefGoogle Scholar
  41. 41.
    Friedman S. Cardiac disease, anxiety, and sexual functioning. Am J Cardiol 2000; 86: 46F–50FPubMedCrossRefGoogle Scholar
  42. 42.
    Drory Y, Kravetz S, Florian V, et al. Sexual activity after first acute myocardial infarction in middle-aged men: demographic, psychological and medical predictors. Cardiology 1998; 90: 207–11PubMedCrossRefGoogle Scholar
  43. 43.
    Buffum J. Pharmacosexology update: prescription drugs and sexual function. J Psychoactive Drugs 1986; 18: 97–106PubMedCrossRefGoogle Scholar
  44. 44.
    Friedman MM, Griffen JA. Relationship of the physical symptoms and physical functioning to depression in patients with heart failure. Heart Lung 2001; 30: 98–104PubMedCrossRefGoogle Scholar
  45. 45.
    Gutierrez RC, Davis T. Assessing depression in patients with congestive heart failure. Can J Cardiovasc Nurs 1999; 10: 29–36Google Scholar
  46. 46.
    Hood S, Robertson I. Erectile dysfunction: a significant health need in patients with coronary heart disease. Scott Med J 2004; 49: 97–8PubMedGoogle Scholar
  47. 47.
    Bochinski D, Lue TF. Medical and surgical therapy of erectile dysfunction. In: McLachlan R, editor. Endnote series on endocrinology of male reproduction: chapter 8 [online]. Available from URL: http://www.endotext.org/male/male8/male8.htm [Accessed 2005 Aug 30]
  48. 48.
    McVary KT, Carrier S, Wessells H. Smoking and erectile dysfunction: evidence based analysis. J Urol 2001; 166: 1624–32PubMedCrossRefGoogle Scholar
  49. 49.
    Derby CA, Mohr BA, Goldstein I, et al. Modifiable risk factors and erectile dysfunction: can lifestyle changes modify risk? Urology 2000; 56: 302–6PubMedCrossRefGoogle Scholar
  50. 50.
    Billups KL, Kaiser DR, Kelly AS, et al. Relation of C-reactive protein and other cardiovascular risk factors to penile vascular disease in men with erectile dysfunction. Int J Impot Res 2003 Aug; 15: 231–6PubMedCrossRefGoogle Scholar
  51. 51.
    Derby CA, Barbour MM, Hume AL, et al. Drug therapy and prevalence of erectile dysfunction in the Massachusetts Male Aging Study cohort. Pharmacotherapy 2001; 21: 676–83PubMedCrossRefGoogle Scholar
  52. 52.
    Silvestri A, Galetta P, Cerquetani E, et al. Report of erectile dysfunction after therapy with beta-blockers is related to patient knowledge of side effects and is reversed by placebo. Eur Heart J 2003; 24: 1928–32PubMedCrossRefGoogle Scholar
  53. 53.
    Cheitlin MD, Hutter Jr AM, Brindis RG, et al. ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology/American Heart Association. J Am Coll Cardiol 1999; 33: 273–82PubMedCrossRefGoogle Scholar
  54. 54.
    Cheitlin MD, Hutter Jr AM, Brindis RG, et al. Use of sildenafil (Viagra) in patients with cardiovascular disease: Technology and Practice Executive Committee. Circulation 1999; 99: 168–77PubMedCrossRefGoogle Scholar
  55. 55.
    Webster LJ, Michelakis ED, Davis T, et al. Use of sildenafil for safe improvement of erectile function and quality of life in men with New York Heart Association classes II and III congestive heart failure: a prospective, placebo-controlled, double-blind crossover trial. Arch Intern Med 2004; 164: 514–20PubMedCrossRefGoogle Scholar
  56. 56.
    Muller JE. Triggering of cardiac events by sexual activity: findings from a case-crossover analysis. Am J Cardiol 2000; 86: 14F–8FPubMedCrossRefGoogle Scholar
  57. 57.
    Stein RA. Cardiovascular response to sexual activity. Am J Cardiol 2000; 86: 27F–9FPubMedCrossRefGoogle Scholar
  58. 58.
    Moller J, Ahlbom A, Hulting J, et al. Sexual activity as a trigger of myocardial infarction: a case-crossover analysis in the Stockholm Heart Epidemiology Programme (SHEEP). Heart 2001; 86: 387–90PubMedCrossRefGoogle Scholar
  59. 59.
    DeBusk RF. Sildenafil and physical exertion in men with coronary artery disease. JAMA 2002; 287: 2359–60PubMedCrossRefGoogle Scholar
  60. 60.
    Servoss SJ, Januzzi JL, Muller JE. Triggers of acute coronary syndromes. Prog Cardiovasc Dis 2002; 44: 369–80PubMedCrossRefGoogle Scholar
  61. 61.
    Cheitlin MD. Should the patient with coronary artery disease use sildenafil? Prev Cardiol 2003; 6: 161–5PubMedCrossRefGoogle Scholar
  62. 62.
    Montorsi F, Briganti A, Salonia A, et al. Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease. Eur Urol 2003; 44: 360–4PubMedCrossRefGoogle Scholar
  63. 63.
    Gazzaruso C, Giordanetti S, De Amici E, et al. Relationship between erectile dysfunction and silent myocardial ischemia in apparently uncomplicated type 2 diabetic patients. Circulation 2004; 110: 22–6PubMedCrossRefGoogle Scholar
  64. 64.
    O’Kane PD, Jackson G. Erectile dysfunction: is there silent obstructive coronary artery disease? Int J Clin Pract 2001; 55: 219–20PubMedGoogle Scholar
  65. 65.
    Kaiser DR, Billups K, Mason C, et al. Impaired brachial artery endothelium-dependent and -independent vasodilation in men with erectile dysfunction and no other clinical cardiovascular disease. J Am Coll Cardiol 2004; 43: 179–84PubMedCrossRefGoogle Scholar
  66. 66.
    Vlachopoulos C, Hirata K, O’Rourke MF. Effect of sildenafil on arterial stiffness and wave reflection. Vasc Med 2003; 8: 243–8PubMedCrossRefGoogle Scholar
  67. 67.
    Lue T. Erectile dysfunction. N Engl J Med 2000; 342: 1802–13PubMedCrossRefGoogle Scholar
  68. 68.
    Morales A, Gingell C, Collins M, et al. Clinical safety of oral sildenafil citrate (VIAGRA) in the treatment of erectile dysfunction. Int J Impot Res 1998; 10: 69–73PubMedCrossRefGoogle Scholar
  69. 69.
    Zippe C, Kedia A, Kedia K, et al. Treatment of erectile dysfunction after radical prostatectomy with sildenafil citrate (Viagra). Urology 1998; 52(6): 963–6PubMedCrossRefGoogle Scholar
  70. 70.
    Chen Q, Wang N, Yao F, et al. Comparison of efficacy and safety of phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction. Zhonghua Nan Ke Xue 2004; 10(4): 302–4PubMedGoogle Scholar
  71. 71.
    Padma-Nathan H. Efficacy and tolerability of tadalafil, a novel phosphodiesterase 5 inhibitor, in treatment of erectile dysfunction. Am J Cardiol 2003; 92(9A): 19M–25MPubMedCrossRefGoogle Scholar
  72. 72.
    Govier F, Potempa AJ, Kaufman J, et al. A multicenter, randomized, double-blind, crossover study of patient preference for tadalafil 20mg or sildenafil citrate 50mg during initiation of treatment for erectile dysfunction. Clin Ther 2003; 25: 2709–23PubMedCrossRefGoogle Scholar
  73. 73.
    Herrmann H, Chang G, Klugherz B, et al. Hemodynamic effects of sildenafil in men with severe coronary artery disease. N Engl J Med 2000; 342(22): 1622–6PubMedCrossRefGoogle Scholar
  74. 74.
    Malozowski S, Sahlroot JT. Sildenafil and physical exertion in men with coronary artery disease. JAMA 2002; 287: 2359–60PubMedCrossRefGoogle Scholar
  75. 75.
    Arruda-Olson AM, Mahoney DW, Nehra A, et al. Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease: a randomized crossover trial. JAMA 2002; 287: 719–25PubMedCrossRefGoogle Scholar
  76. 76.
    Thadani U, Smith W, Nash S, et al. The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J Am Coll Cardiol 2002; 40: 2006–12PubMedCrossRefGoogle Scholar
  77. 77.
    Michelakis ED, Tymchak W, Noga M, et al. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 2003; 108: 2066–9PubMedCrossRefGoogle Scholar
  78. 78.
    Thebaud B, Michelakis E, Wu XC, et al. Sildenafil reverses O2 constriction of the rabbit ductus arteriosus by inhibiting type 5 phosphodiesterase and activating BK(Ca) channels. Pediatr Res 2002; 52: 19–24PubMedCrossRefGoogle Scholar
  79. 79.
    Vardi Y, Klein L, Nassar S, et al. Effects of sildenafil citrate (Viagra) on blood pressure in normotensive and hypertensive men. Urology 2002; 59: 747–52PubMedCrossRefGoogle Scholar
  80. 80.
    Bocchi EA, Guimaraes G, Mocelin A, et al. Sildenafil effects on exercise, neurohormonal activation, and erectile dysfunction in congestive heart failure: a double-blind, placebo-controlled, randomized study followed by a prospective treatment for erectile dysfunction. Circulation 2002; 106: 1097–103PubMedCrossRefGoogle Scholar
  81. 81.
    Pryor JP. Safety of sildenafil. Curr Opin Urol 2000; 10: 613–5PubMedCrossRefGoogle Scholar
  82. 82.
    Muller J, Mittleman A, Maclure M, et al. Triggering myocardial infarction by sexual activity: low absolute risk and prevention by regular physical exertion. Determinants of Myocardial Infarction Onset Study Investigators. JAMA 1996; 275(18): 1405–9PubMedCrossRefGoogle Scholar
  83. 83.
    Witherington R. Vacuum constriction device for management of erectile impotence. J Urol 1989; 141: 320–2PubMedGoogle Scholar
  84. 84.
    Cookson MS, Nadig PW. Long-term results with vacuum constriction device. J Urol 1993; 149: 290–4PubMedGoogle Scholar
  85. 85.
    Padma-Nathan H, Hellstrom WJ, Kaiser FE, et al. Treatment of men with erectile dysfunction with transurethral alprostadil: Medicated Urethral System for Erection (MUSE) Study Group. N Engl J Med 1997; 336: 1–7PubMedCrossRefGoogle Scholar
  86. 86.
    Lewis RW. Transurethral alprostadil with MUSE (medicated urethral system for erection) vs intracavernous alprostadil: a comparative study in 103 patients with erectile dysfunction. Int J Impot Res 1998; 10: 61–2PubMedCrossRefGoogle Scholar
  87. 87.
    Porst H. The rationale for prostaglandin E1 in erectile failure: a survey of worldwide experience. J Urol 1996; 155: 802–15PubMedCrossRefGoogle Scholar
  88. 88.
    Porst H. Transurethral alprostadil with MUSE (medicated urethral system for erection) vs intracavernous alprostadil: a comparative study in 103 patients with erectile dysfunction. Int J Impot Res 1997; 9: 187–92PubMedCrossRefGoogle Scholar
  89. 89.
    Werthman P. MUSE therapy: preliminary clinical observations. Urology 1997; 50: 809–11PubMedCrossRefGoogle Scholar
  90. 90.
    Kurt U, Ozkardes H, Altug U, et al. The efficacy of anti-serotoninergic agents in the treatment of erectile dysfunction. J Urol 1994; 152: 407–9PubMedGoogle Scholar
  91. 91.
    Mirone V, Imbimbo C, Fabrizio F, et al. Ketanserin plus pros-taglandin E1 (PGE-1) as intracavernosal therapy for patients with erectile dysfunction unresponsive to PGE-1 alone. Br J Urol 1996; 77: 736–9PubMedCrossRefGoogle Scholar
  92. 92.
    Jeremy J, Ballard S, Naylor A, et al. Effects of sildenafil, a type-5 cGMP phosphodiesterase inhibitor, and papaverine on cyclic GMP and cyclic AMP levels in the rabbit corpus cavernosum in vitro. Br J Urol 1997; 79: 958–63PubMedCrossRefGoogle Scholar
  93. 93.
    Earle CM, Keogh EJ, Wisniewski ZS, et al. Prostaglandin E1 therapy for impotence, comparison with papaverine. J Urol 1990; 143: 57–9PubMedGoogle Scholar
  94. 94.
    Lakin MM, Montague DK, VanderBrug Medendorp S, et al. Intracavernous injection therapy: analysis of results and complications. J Urol 1990; 143: 1138–41PubMedGoogle Scholar
  95. 95.
    Fallon B. Intracavernous injection therapy for male erectile dysfunction. Urol Clin North Am 1995; 22: 833–45PubMedGoogle Scholar
  96. 96.
    Stief C, Wetterauer U. Erectile responses to intracavernous papaverine and phentolamine: comparison of single and combined delivery. J Urol 1988; 140: 1415–6PubMedGoogle Scholar
  97. 97.
    Canale D, Giorgi PM, Lencioni R, et al. Long-term intra-cavernous self-injection with prostaglandin E1 for the treatment of erectile dysfunction. Int J Androl 1996; 19: 28–32PubMedCrossRefGoogle Scholar
  98. 98.
    Chew K, Stuckey B, Earle C, et al. Penile fibrosis in intra-cavernosal prostaglandin E1 injection therapy for erectile dysfunction. Int J Impot Res 1997; 9: 225–9PubMedCrossRefGoogle Scholar
  99. 99.
    Linet O, Neff L. Intracavernous prostaglandin E1 in erectile dysfunction. Clin Investig 1994; 72: 139–49PubMedCrossRefGoogle Scholar
  100. 100.
    Israilov S, Niv E, Livne PM, et al. Intracavernous injections for erectile dysfunction in patients with cardiovascular diseases and failure or contraindications for sildenafil citrate. Int J Impot Res 2002; 14: 38–43PubMedCrossRefGoogle Scholar
  101. 101.
    Kiely E, Bloom S, Williams G. Penile response to intracavernosal vasoactive intestinal polypeptide alone and in combination with other vasoactive agents. Br J Urol 1989; 64: 191–4PubMedCrossRefGoogle Scholar
  102. 102.
    Dinsmore W, Alderdice D. Vasoactive intestinal polypeptide and phentolamine mesylate administered by autoinjector in the treatment of patients with erectile dysfunction resistant to other intracavernosal agents. Br J Urol 1998; 81: 437–40PubMedCrossRefGoogle Scholar
  103. 103.
    Zaher T. Papaverine plus prostaglandin E1 versus prostaglandin E1 alone for intracorporeal injection therapy. Int Urol Nephrol 1998; 30: 193–6PubMedCrossRefGoogle Scholar
  104. 104.
    Meinhardt W, de la Fuente R, Lycklama a Nijeholt A, et al. Prostaglandin E1 with phentolamine for the treatment of erectile dysfunction. Int J Impot Res 1996; 8: 5–7PubMedGoogle Scholar
  105. 105.
    Bennett A, Carpenter A, Barada J. An improved vasoactive drug combination for a pharmacological erection program. J Urol 1991; 146(6): 1564–5PubMedGoogle Scholar
  106. 106.
    Gupta R, Kirschen J, Barrow RN, et al. Predictors of success and risk factors for attrition in the use of intracavernous injection. J Urol 1997; 157: 1681–6PubMedCrossRefGoogle Scholar
  107. 107.
    Weiss J, Badlani G, Ravalli R, et al. Reasons for high drop-out rate with self-injection therapy for impotence. Int J Impot Res 1994; 6: 171–4PubMedGoogle Scholar
  108. 108.
    Ernst E, Pittler MH. Yohimbine for erectile dysfunction: a systematic review and meta-analysis of randomized clinical trials. J Urol 1998; 159(2): 433–6PubMedCrossRefGoogle Scholar
  109. 109.
    Gwinup G. Oral phentolamine in nonspecific erectile insufficiency. Ann Intern Med 1988; 109(2): 162–3PubMedGoogle Scholar
  110. 110.
    Zorgniotti A. Experience with buccal phentolamine mesylate for impotence. Int J Impot Res 1994; 6: 37–41PubMedGoogle Scholar
  111. 111.
    Heaton J, Morales A, Adams M, et al. Recovery of erectile function by the oral administration of apomorphine. Urology 1995; 45: 200–6PubMedCrossRefGoogle Scholar
  112. 112.
    Gomaa A, Shalaby M, Osman M, et al. Topical treatment of erectile dysfunction: randomised double blind placebo controlled trial of cream containing aminophylline, isosorbide dinitrate, and co-dergocrine mesylate. BMJ 1996; 312: 1512–5PubMedCrossRefGoogle Scholar
  113. 113.
    Hermann M, Berger P. Hormonal changes in aging men: a therapeutic indication? Exp Gerontol 2001; 36: 1075–82PubMedCrossRefGoogle Scholar
  114. 114.
    Buvat J, Lemaire A. Endocrine screening in 1022 men with erectile dysfunction: clinical significance and cost-effective strategy. J Urol 1997; 158: 1764–7PubMedCrossRefGoogle Scholar
  115. 115.
    Newerla G. The history of the discovery and isolation of the male hormone. N Engl J Med 1943; 228: 39–47CrossRefGoogle Scholar
  116. 116.
    Brown-Sequard E. The effects produced in man by subcutaneus injections of a liquid obtained from the testicles of animals. Lancet 1889; II: 105–7CrossRefGoogle Scholar
  117. 117.
    Heim N. Sexual behavior of castrated sex offenders. Arch Sex Behav 1981; 10: 11–9PubMedCrossRefGoogle Scholar
  118. 118.
    Morales A, Johnston B, Heaton JW, et al. Oral androgens in the treatment of hypogonadal impotent men. J Urol 1994; 152: 1115–8PubMedGoogle Scholar
  119. 119.
    Arver S, Dobs AS, Meikle AW, et al. Improvement of sexual function in testosterone deficient men treated for 1 year with a permeation enhanced testosterone transdermal system. J Urol 1996; 155(5): 1604–8PubMedCrossRefGoogle Scholar
  120. 120.
    Jain P, Rademaker AW, McVary KT. Testosterone supplementation for erectile dysfunction: results of a meta-analysis. J Urol 2000; 164(2): 371–5PubMedCrossRefGoogle Scholar
  121. 121.
    Segraves RT. Emerging therapies for female sexual dysfunction. Expert Opin Emerg Drugs 2003; 8: 515–22PubMedCrossRefGoogle Scholar
  122. 122.
    Argiolas A, Melis MR. The neurophysiology of the sexual cycle. J Endocrinol Invest 2003; 26: 20–2PubMedGoogle Scholar
  123. 123.
    Schober JM, Meyer-Bahlburg HF, Ransley PG. Self-assessment of genital anatomy, sexual sensitivity and function in women: implications for genitoplasty. BJU Int 2004; 94: 589–94PubMedCrossRefGoogle Scholar
  124. 124.
    Billups KL, Berman L, Berman J, et al. A new non-pharmacological vacuum therapy for female sexual dysfunction. J Sex Marital Ther 2001; 27: 435–41PubMedCrossRefGoogle Scholar
  125. 125.
    Basson R, Berman J, Burnett A, et al. Report of the international consensus development conference on female sexual dysfunction: definitions and classifications. J Urol 2000; 163: 888–93PubMedCrossRefGoogle Scholar
  126. 126.
    Ragucci KR, Culhane NS. Treatment of female sexual dysfunction. Ann Pharmacother 2003; 37: 546–55PubMedCrossRefGoogle Scholar
  127. 127.
    Berman JR, Berman LA, Werbin TJ, et al. Female sexual dysfunction: anatomy, physiology, evaluation and treatment options. Curr Opin Urol 1999; 9: 563–8PubMedCrossRefGoogle Scholar
  128. 128.
    Park K, Tarcan T, Goldstein I, et al. Atherosclerosis-induced chronic arterial insufficiency causes clitoral cavernosal fibrosis in the rabbit. Int J Impot Res 2000; 12: 111–6PubMedCrossRefGoogle Scholar
  129. 129.
    Erol B, Tefekli A, Ozbey I, et al. Sexual dysfunction in type II diabetic females: a comparative study. J Sex Marital Ther 2002; 28Suppl. 1: 55–62PubMedCrossRefGoogle Scholar
  130. 130.
    Erol B, Tefekli A, Sanli O, et al. Does sexual dysfunction correlate with deterioration of somatic sensory system in diabetic women? Int J Impot Res 2003; 15: 198–202PubMedCrossRefGoogle Scholar
  131. 131.
    Berman JR, Berman LA, Werbin TJ, et al. Clinical evaluation of female sexual function: effects of age and estrogen status on subjective and physiologic sexual responses. Int J Impot Res 1999; 11Suppl. 1: S31–8PubMedCrossRefGoogle Scholar
  132. 132.
    Park K, Ahn K, Lee S, et al. Decreased circulating levels of estrogen alter vaginal and clitoral blood flow and structure in the rabbit. Int J Impot Res 2001; 13: 116–24PubMedCrossRefGoogle Scholar
  133. 133.
    MacRitchie AN, Jun SS, Chen Z, et al. Estrogen upregulates endothelial nitric oxide synthase gene expression in fetal pulmonary artery endothelium. Circ Res 1997; 81: 355–62PubMedCrossRefGoogle Scholar
  134. 134.
    Gragasin FS, Xu Y, Arenas IA, et al. Estrogen reduces angiotensin II-induced nitric oxide synthase and NAD(P)H oxidase expression in endothelial cells. Arterioscler Thromb Vasc Biol 2003; 23: 38–44PubMedCrossRefGoogle Scholar
  135. 135.
    Rosenfeld CR, Roy T, Cox BE. Mechanisms modulating estrogen-induced uterine vasodilation. Vascul Pharmacol 2002; 38: 115–25PubMedCrossRefGoogle Scholar
  136. 136.
    Holdiman AJ, Fergus DJ, England SK. 17beta-Estradiol upregulates distinct maxi-K channel transcripts in mouse uterus. Mol Cell Endocrinol 2002; 192: 1–6PubMedCrossRefGoogle Scholar
  137. 137.
    Node K, Kitakaze M, Kosaka H, et al. Roles of NO and Ca2+-activated K+ channels in coronary vasodilation induced by 17beta-estradiol in ischemic heart failure. FASEB J 1997; 11: 793–9PubMedGoogle Scholar
  138. 138.
    Valverde MA, Rojas P, Amigo J, et al. Acute activation of Maxi-K channels (hSlo) by estradiol binding to the beta subunit. Science 1999; 285: 1929–31PubMedCrossRefGoogle Scholar
  139. 139.
    Gonzalez M, Viafara G, Caba F, et al. Sexual function, menopause and hormone replacement therapy (HRT). Maturitas 2004; 48: 411–20PubMedCrossRefGoogle Scholar
  140. 140.
    Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002; 288: 49–57PubMedCrossRefGoogle Scholar
  141. 141.
    Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women: Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280: 605–13PubMedCrossRefGoogle Scholar
  142. 142.
    Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003; 349: 523–34PubMedCrossRefGoogle Scholar
  143. 143.
    Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002; 288: 321–33PubMedCrossRefGoogle Scholar
  144. 144.
    Ylikorkala O. HRT as secondary prevention of cardiovascular disease. Maturitas 2004; 47: 315–8PubMedCrossRefGoogle Scholar
  145. 145.
    Enzlin P, Mathieu C, Van Den Bruel A, et al. Prevalence and predictors of sexual dysfunction in patients with type 1 diabetes. Diabetes Care 2003; 26: 409–14PubMedCrossRefGoogle Scholar
  146. 146.
    Cheung RT. Sexual functioning in Chinese stroke patients with mild or no disability. Cerebrovasc Dis 2002; 14: 122–8PubMedCrossRefGoogle Scholar
  147. 147.
    Korpelainen JT, Nieminen P, Myllyla VV. Sexual functioning among stroke patients and their spouses. Stroke 1999; 30: 715–9PubMedCrossRefGoogle Scholar
  148. 148.
    Kimura M, Murata Y, Shimoda K, et al. Sexual dysfunction following stroke. Compr Psychiatry 2001; 42: 217–22PubMedCrossRefGoogle Scholar
  149. 149.
    Monga TN, Lawson JS, Inglis J. Sexual dysfunction in stroke patients. Arch Phys Med Rehabil 1986; 67: 19–22PubMedGoogle Scholar
  150. 150.
    Marinkovic S, Badlani G. Voiding and sexual dysfunction after cerebrovascular accidents. J Urol 2001; 165: 359–70PubMedCrossRefGoogle Scholar
  151. 151.
    Choi-Kwon S, Kim JS. Poststroke emotional incontinence and decreased sexual activity. Cerebrovasc Dis 2002; 13: 31–7PubMedCrossRefGoogle Scholar
  152. 152.
    Enzlin P, Mathieu C, Van den Bruel A, et al. Sexual dysfunction in women with type 1 diabetes: a controlled study. Diabetes Care 2002; 25: 672–7PubMedCrossRefGoogle Scholar
  153. 153.
    Jackson G. Sexual dysfunction and diabetes. Int J Clin Pract 2004; 58: 358–62PubMedCrossRefGoogle Scholar
  154. 154.
    Tuomilehto J. Impact of age on cardiovascular risk: implications for cardiovascular disease management. Atheroscler Suppl 2004; 5: 9–17PubMedCrossRefGoogle Scholar
  155. 155.
    Park K, Goldstein I, Andry C, et al. Vasculogenic female sexual dysfunction: the hemodynamic basis for vaginal engorgement insufficiency and clitoral erectile insufficiency. Int J Impot Res 1997; 9: 27–37PubMedCrossRefGoogle Scholar
  156. 156.
    Goldstein I, Berman JR. Vasculogenic female sexual dysfunction: vaginal engorgement and clitoral erectile insufficiency syndromes. Int J Impot Res 1998; 10Suppl. 2: S84–90PubMedGoogle Scholar
  157. 157.
    Park K, Ahn K, Chang JS, et al. Diabetes induced alteration of clitoral hemodynamics and structure in the rabbit. J Urol 2002; 168: 1269–72PubMedCrossRefGoogle Scholar
  158. 158.
    Bechara AJ, Cao G, Casabe AR, et al. Morphological modifications in clitoris and vagina in spontaneously hypertensive rats. Int J Impot Res 2003; 15: 166–72PubMedCrossRefGoogle Scholar
  159. 159.
    Hodge RH, Harward MP, West MS, et al. Sexual function of women taking antihypertensive agents: a comparative study. J Gen Intern Med 1991; 6: 290–4PubMedCrossRefGoogle Scholar
  160. 160.
    Haas CA, Seftel AD, Razmjouei K, et al. Erectile dysfunction in aging: upregulation of endothelial nitric oxide synthase. Urology 1998; 51: 516–22PubMedCrossRefGoogle Scholar
  161. 161.
    Guay AT. Sexual dysfunction in the diabetic patient. Int J Impot Res 2001; 13Suppl. 5: S47–50PubMedCrossRefGoogle Scholar
  162. 162.
    Lin JS, Tsai YS, Lin YM, et al. Age-associated changes in collagen content and its subtypes within rat corpora cavernosa with computerized histomorphometric analysis. Urology 2001; 57: 837–42PubMedCrossRefGoogle Scholar
  163. 163.
    Caruso S, Agnello C, Intelisano G, et al. Placebo-controlled study on efficacy and safety of daily apomorphine SL intake in premenopausal women affected by hypoactive sexual desire disorder and sexual arousal disorder. Urology 2004; 63: 955–9PubMedCrossRefGoogle Scholar
  164. 164.
    Rubio-Aurioles E, Lopez M, Lipezker M, et al. Phentolamine mesylate in postmenopausal women with female sexual arousal disorder: a psychophysiological study. J Sex Marital Ther 2002; 28Suppl. 1: 205–15PubMedCrossRefGoogle Scholar
  165. 165.
    Padma-Nathan H, Brown C, Fendl J, et al. Efficacy and safety of topical alprostadil cream for the treatment of female sexual arousal disorder (FSAD): a double-blind, multicenter, randomized, and placebo-controlled clinical trial. J Sex Marital Ther 2003; 29: 329–44PubMedCrossRefGoogle Scholar
  166. 166.
    Berman J, Shuker J, Goldstein I. Female sexual dysfunction. In: Carson C, Goldstein I, Kirby RS, editors. Textbook of erectile dysfunction. Vol xviii, 659. Oxford: ISIS Medical Media, 1999: 627–38Google Scholar
  167. 167.
    Shifren JL. The role of androgens in female sexual dysfunction. Mayo Clin Proc 2004 Apr; 79: S19–24PubMedGoogle Scholar
  168. 168.
    Traish AM, Kim N, Min K, et al. Role of androgens in female genital sexual arousal: receptor expression, structure, and function. Fertil Steril 2002; 77Suppl. 4: 11–8CrossRefGoogle Scholar
  169. 169.
    McCredie RJ, McCrohon JA, Turner L, et al. Vascular reactivity is impaired in genetic females taking high-dose androgens. J Am Coll Cardiol 1998; 32: 1331–5PubMedCrossRefGoogle Scholar
  170. 170.
    D’Amati G, di Gioia CR, Bologna M, et al. Type 5 phosphodiesterase expression in the human vagina. Urology 2002; 60: 191–5PubMedCrossRefGoogle Scholar
  171. 171.
    Park K, Moreland RB, Goldstein I, et al. Sildenafil inhibits phosphodiesterase type 5 in human clitoral corpus cavernosum smooth muscle. Biochem Biophys Res Commun 1998; 249: 612–7PubMedCrossRefGoogle Scholar
  172. 172.
    Walsh KE, Berman JR, Berman LA, et al. Safety and efficacy of topical nitroglycerin for treatment of vulvar pain in women with vulvodynia: a pilot study. J Gend Specif Med 2002; 5: 21–7PubMedGoogle Scholar
  173. 173.
    Berman JR, Berman LA, Lin H, et al. Effect of sildenafil on subjective and physiologic parameters of the female sexual response in women with sexual arousal disorder. J Sex Marital Ther 2001; 27: 411–20PubMedCrossRefGoogle Scholar
  174. 174.
    Shen WW, Urosevich Z, Clayton DO. Sildenafil in the treatment of female sexual dysfunction induced by selective serotonin reuptake inhibitors. J Reprod Med 1999; 44: 535–42PubMedGoogle Scholar
  175. 175.
    Sipski ML, Rosen RC, Alexander CJ, et al. Sildenafil effects on sexual and cardiovascular responses in women with spinal cord injury. Urology 2000; 55: 812–5PubMedCrossRefGoogle Scholar
  176. 176.
    Dasgupta R, Wiseman OJ, Kanabar G, et al. Efficacy of sildenafil in the treatment of female sexual dysfunction due to multiple sclerosis. J Urol 2004; 171: 1189–93PubMedCrossRefGoogle Scholar
  177. 177.
    Kaplan SA, Reis RB, Kohn IJ, et al. Safety and efficacy of sildenafil in postmenopausal women with sexual dysfunction. Urology 1999; 53: 481–6PubMedCrossRefGoogle Scholar
  178. 178.
    Min K, Kim NN, McAuley I, et al. Sildenafil augments pelvic nerve-mediated female genital sexual arousal in the anesthetized rabbit. Int J Impot Res 2000; 12Suppl. 3: S32–9PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  • Stephen L. Archer
    • 1
  • Ferrante S. Gragasin
    • 2
  • Linda Webster
    • 2
  • Derek Bochinski
    • 3
  • Evangelos D. Michelakis
    • 2
  1. 1.Department of Medicine (Cardiology), Department of Physiology and the Vascular Biology GroupUniversity of AlbertaEdmontonCanada
  2. 2.Department of Medicine (Cardiology) and the Vascular Biology GroupUniversity of AlbertaEdmontonCanada
  3. 3.Department of Surgery, Division of UrologyUniversity of AlbertaEdmontonCanada

Personalised recommendations